10x Genomics (TXG) Receivables - Net (2018 - 2025)
10x Genomics (TXG) has disclosed Receivables - Net for 8 consecutive years, with $47.0 million as the latest value for Q4 2025.
- Quarterly Receivables - Net fell 46.49% to $47.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $47.0 million through Dec 2025, down 46.49% year-over-year, with the annual reading at $47.0 million for FY2025, 46.49% down from the prior year.
- Receivables - Net hit $47.0 million in Q4 2025 for 10x Genomics, up from $43.8 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $114.8 million in Q4 2023 to a low of $43.8 million in Q3 2025.
- Historically, Receivables - Net has averaged $77.6 million across 5 years, with a median of $81.0 million in 2021.
- Biggest five-year swings in Receivables - Net: skyrocketed 162.61% in 2021 and later plummeted 47.59% in 2025.
- Year by year, Receivables - Net stood at $85.3 million in 2021, then grew by 22.24% to $104.2 million in 2022, then grew by 10.19% to $114.8 million in 2023, then dropped by 23.49% to $87.9 million in 2024, then plummeted by 46.49% to $47.0 million in 2025.
- Business Quant data shows Receivables - Net for TXG at $47.0 million in Q4 2025, $43.8 million in Q3 2025, and $50.0 million in Q2 2025.